Israel Englander Dia Medica Therapeutics Inc. Transaction History

Millennium Management LLC

$199 Billion
Q3 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Dia Medica Therapeutics Inc. stock. As of the latest transaction made, Millennium Management LLC holds 33,690 shares of DMAC stock, worth $150,931. This represents 0.0% of its overall portfolio holdings.

Number of Shares

33,690

Holding current value

$150,931

% of portfolio

0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$2.8 - $4.49 $94,332 - $151,268	33,690 New	33,690 $141,000
Q4 2023 Feb 14, 2024	BUY	$2.05 - $2.99 $59,132 - $86,246	28,845 New	28,845 $81,000
Q1 2022 May 16, 2022	SELL	$2.29 - $3.88 $50,950 - $86,326	-22,249 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$3.43 - $4.65 $76,314 - $103,457	22,249 New	22,249 $83,000
Q3 2021 Nov 15, 2021	SELL	$3.1 - $4.32 $64,139 - $89,380	-20,690 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$4.45 - $9.91 $220,679 - $491,446	-49,591 Reduced 70.56%	20,690 $92,000
Q1 2021 May 17, 2021	BUY	$7.76 - $10.43 $228,299 - $306,850	29,420 Added 72.0%	70,281 $643,000
Q4 2020 Feb 16, 2021	BUY	$4.13 - $10.14 $168,755 - $414,330	40,861 New	40,861 $414,000
Q2 2020 Aug 14, 2020	SELL	$2.6 - $7.32 $28,267 - $79,583	-10,872 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$2.25 - $5.64 $49,704 - $124,593	-22,091 Reduced 67.02%	10,872 $30,000
Q4 2019 Feb 14, 2020	SELL	$1.8 - $5.04 $68,320 - $191,298	-37,956 Reduced 53.52%	32,963 $160,000
Q3 2019 Nov 14, 2019	SELL	$2.07 - $4.88 $58,831 - $138,694	-28,421 Reduced 28.61%	70,919 $145,000
Q2 2019 Aug 15, 2019	BUY	$2.7 - $4.96 $144,336 - $265,151	53,458 Added 116.51%	99,340 $493,000
Q2 2019 Aug 14, 2019	BUY	$2.7 - $4.96 $123,881 - $227,574	45,882 New	45,882 $2.61 Million

Others Institutions Holding DMAC

# of Institutions

Shares Held

4.22M

Call Options Held

8.2K

Put Options Held

200

View Full List

About DiaMedica Therapeutics Inc.

Ticker DMAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,443,100
Market Cap $118M
Description
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...

More about DMAC

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account